Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers

Teodorikez Wilfox
Jimenez-Rodriguez¹–³
Marlene Garcia-Neuer¹
Leila A Alenazy¹,⁴
Mariana Castells¹

¹Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; ²Allergy Section, Alicante General University Hospital, Alicante, Spain; ³PhD Program in Public Health, Medical and Surgical Sciences, Miguel Hernandez University, Alicante, Spain; ⁴Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Abstract: Anaphylaxis is the most serious of all allergic reactions and can be fatal. The diagnosis is frequently delayed, and misdiagnosis often occurs with asthma or urticaria. Biomarkers such as tryptase are not routinely checked, and appropriate treatment with epinephrine is not administered in a majority of cases, increasing the risk of poor outcomes. The objective of this review is to provide a better understanding of the pathophysiology of anaphylaxis with a description of phenotypes, endotypes, and biomarkers available in both the clinical and research settings. Expanding knowledge with regard to the presentation, causes, and triggers for anaphylaxis among healthcare providers will improve its diagnosis and management, increase patient safety, and decrease morbidity and mortality.

Keywords: anaphylaxis, hypersensitivity reactions, tryptase, autoimmune progesterone dermatitis, epinephrine, precision medicine

Defining anaphylaxis: history and consensus

In 1839, François Magendie was the first to describe the phenomenon of anaphylaxis experimentally when he found that rabbits that were able to tolerate a single injection of egg albumin often died after the second or third injection. He assumed these reactions were “toxic” because the injected albumin in these animals acted as a poison.¹ In 1902, Charles Richet and Paul Portier coined the term anaphylaxis from ana (against) and phylaxia (protection) in Greek for the “property that has a poison to lower immunity rather than reinforce it.”² Current expert consensus has defined anaphylaxis as a serious allergic reaction that is rapid in onset and can be fatal.³ The diagnosis is based on three possible clinical scenarios:

1. Sudden onset of an illness (minutes to hours) with involvement of the skin, mucosal tissue (or both), and at least one of the following: a) respiratory compromise and b) reduced blood pressure or symptoms of end-organ dysfunction;
2. Two or more of the following that occur after exposure to a likely allergen or other triggers (minutes to several hours): skin/mucosal symptoms and signs, respiratory compromise, reduced blood pressure or associated symptoms, and/or gastrointestinal symptoms (crampy abdominal pain or vomiting).
3. Reduced blood pressure after exposure to a known allergen (minutes to hours).⁵

Critically, anaphylaxis involves at least two organ systems or sudden changes in vital signs. Skin and mucosal changes are usually but not always present, whereas hypotension and shock features are not mandatory for the diagnosis.⁶,⁷

Correspondence: Mariana Castells
Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, The Building for Transformative Medicine, 5th Floor, Room 5002N, 60 Fenwood Road, Boston, MA 02115, USA
Tel +1 617 525 1265
Fax +1 617 525 1310
Email mcastells@bwh.harvard.edu
Anaphylactoid reactions are clinically indistinguishable from anaphylaxis, with no demonstrable involvement of immunoglobulin E (IgE), and the term is no longer used, mainly to avoid unnecessary delays in diagnosis and treatment.3,8,9

Despite advances in the field of allergy, the symptoms of anaphylaxis continue to be under-recognized, diagnosis is often missed, treatment is often delayed (including the lack of epinephrine use), and the underlying causes are under-investigated worldwide.5,7,10

In 2003, to homogenize the nomenclature of allergy worldwide, the World Allergy Organization (WAO) proposed two classifications of anaphylaxis on the basis of the pathophysiological mechanism involved in the reaction. The term allergic anaphylaxis denotes reactions mediated by an immunologic mechanism – for example, IgE-, Ig, or an immune complex complement-related (corresponding to the classic hypersensitivity reactions [HSRs] described by Gell and Coombs) pathways. The term non-allergic anaphylaxis denotes reactions mediated by other mechanisms (eg, direct activation by bradykinin or complement), which are usually triggered by agents or events that induce sudden mast cell or basophil activation.11

Between 2004 and 2005, several organizations came together to update the definition and emphasize the use of epinephrine as a first-line treatment for anaphylaxis.5,12 Several studies were carried out to validate the criteria and to expand the scientific evidence with regard to the pathophysiology, triggers, and clinical management of anaphylaxis. The WAO provided a consensus document for the diagnosis and treatment of anaphylaxis. This report has been reviewed and updated to incorporate changes based on updated scientific evidence.3,4,8,9

Recently, a consensus document between the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology was published, which summarizes current knowledge in the field of allergy. They proposed a new approach based on precision medicine through phenotypes, which is associated with specific mechanisms that are defined as endotypes and the associated diagnostic biomarkers in food and drug allergies and anaphylaxis.13 This new classification encompasses the classic HSRs described by Gell and Coombs as well as reactions outside the classification.14

Phenotypes, endotypes, and biomarkers of anaphylaxis

Phenotypes are defined by clinical presentation, and endotypes refer to the cellular and molecular mechanisms of the HSRs defined by the diagnostic biomarkers (skin testing, tryptase, IgE, interleukin [IL]-6, and others).

Phenotypes of anaphylaxis are classified, by their clinical presentation, into Type I reactions, cytokine-release reactions (CRRs), mixed reactions, and, finally, bradykinin- and complement-like reactions. The corresponding endotypes underlying these phenotypes include IgE- and non–IgE-mediated mechanisms, cytokine-mediated mechanisms, mixed processes, and direct activation of immune cells by either complement or bradykinin14 (Figure 1).

Type I

IgE-mediated anaphylaxis is the major mechanism underlying allergic anaphylaxis.7 After exposure to the allergen, a series of signals trigger the production of allergen-specific IgE by B cells (sensitization phenomenon). In subsequent exposures, the antigen–allergen-specific IgE complex binds to the Fc-epsilon-RI receptor on mast cells and/or basophils and, with adequate signaling, activates and degranulates these cells, thereby releasing preformed mediators, enzymes, and cytokines and facilitating the synthesis of de novo inflammatory mediators (eg, tryptase, histamine, leukotrienes, prostaglandins, platelet-activating factor [PAF], cytokines).15,16

The mediators cause allergic symptoms by directly acting on tissues. The reaction is propagated by recruiting and activating additional inflammatory cells – particularly eosinophils, which release more mediators, including lipid-derived mediators such as prostaglandin D2 and cysteinyl leukotrienes.16

In addition to the classical pathway mediated by IgE, other possible pathways have been described in animal models that are difficult to explore in humans.17 One of these alternative pathways is similar to the IgE-mediated pathway, but involves IgG antibodies. IgG-mediated reactions are mediated by IgG complexes that cross-link to the macrophage low-affinity receptor (FcgRIII) thus stimulating PAF (rather than histamine) release.18

PAF causes platelet aggregation and release of the potent vasoconstrictor thromboxane A2 and serotonin; acts directly on vascular endothelial cells to increase vascular permeability; decreases cardiac output, which can produce hypotension and cardiac dysfunctions; and increases smooth muscle contraction in the airways, gut, and uterus, among other effects.19,20

Although IgG-dependent anaphylaxis has not been demonstrated in humans, it has been hypothesized that IgG antibodies can mediate systemic anaphylaxis if there are large numbers of both IgG and antigen present.21 IgG receptors are capable of activating macrophages and neutrophils to
Phenotypes, endotypes, and biomarkers of anaphylaxis

Secretory PAF and activate mast cells in vitro, which may contribute to human anaphylaxis. Chimeric IgG monoclonal antibodies (mAbs), such as rituximab, have been shown to induce anaphylaxis even in the absence of IgE, suggesting IgG-dependent anaphylaxis.

Recent reports with regard to the direct activation of mast cells, independent of those mediated by IgE, indicate that the human G-protein–coupled receptor – MRGPRX2 – may be the receptor for many drugs and cationic proteins, such as quinolone antibiotics (eg, ciprofloxacin, levofloxacin), general anesthetics such as atracurium and rocuronium, icatibant, and other drugs with tetrahydroisoquinoline (THIQ) motifs.

The endotype for IgE-mediated reactions is mast cell and basophil mediator release that causes flushing, pruritus, hives, angioedema, shortness of breath, wheezing, nausea, vomiting, diarrhea, hypotension, oxygen desaturation, and cardiovascular collapse along with other symptoms.

The common triggers for these reactions include foods, drugs, latex, Hymenoptera venoms, and environmental allergens. There are important geographic and age-related variations between countries; however, the most common food allergens are peanut, milk, eggs, nuts, shellfish, fruits, and vegetables; antibiotics such as β-lactams, nonsteroidal anti-inflammatory drugs (NSAIDs), chemotherapeutic agents such as platins and taxanes, chimeric humanized human mAbs, general anesthetics, and immunotherapy allergens are other common allergens both in children and adults.

CRRs

The CRR phenotype is caused by the release of proinflammatory mediators such as tumor necrosis factor alpha (TNF-α), IL-1β, and IL-6, and their target cells (endotype) include monocytes, macrophages, mast cells, and other immune cells with the Fc gamma receptor (FcgR) – an essential participant in many immune system effector functions, including the
release of inflammatory mediators and antibody-dependent cellular cytotoxicity.

Triggers for these reactions include chimeric, humanized, and human mAbs and chemotherapeutic agents, including oxaliplatin. These drugs have not only been used to treat neoplastic, autoimmune, and inflammatory diseases but also to treat allergic disorders including allergic asthma, eosinophilic asthma, and chronic urticaria. HSRs to biologic agents are less common than standard infusion reactions, and they vary based on the biological agents involved. Phenotypic symptoms include chills, fever, and pain; these respond to ibuprofen and fluids and have been clinically correlated with IL-6. CRRs are typically not as severe as cytokine storm reactions.

IL-6 is an excellent biomarker and, eventually, disseminated intravascular coagulation (DIC) reactions such as redness, pruritus, urticaria, angioedema, difficulty breathing, wheezing, nausea, vomiting, diarrhea, hypotension, desaturation, cardiovascular collapse, and life-threatening anaphylaxis – occurring secondary to the release of mast cell/basophil mediators (tryptase, histamine, leukotrienes, and prostaglandins) – overlap with symptoms secondary to the release of proinflammatory cytokines and chemokines (IL-1β, IL-6, and TNF-α) such as chills, fever, malaise, hypotension, desaturation, and cardiovascular collapse, thereby making it impossible to differentiate between mechanisms.

**Complement/bradykinin-like reactions**

Complement reactions involve direct activation of mast cells and other immune cells through complement activation as well as direct and indirect activation of the intrinsic coagulation pathway. Immune complexes can activate the complement system, generating anaphylatoxins such as C3a and C5a, which can bind to complement receptors resulting in release of histamine, leukotrienes, and prostaglandins that can induce flushing, hives, hypoxia, vasodilation, and hypotension. This mechanism has been described with drugs such as vancomycin, contrast media, dialysis membranes, and infusions of drugs that are suspended in certain lipid vehicles such as Cremophor EL, polysorbate 80, and polyethylene glycol. Notably, reports have also suggested that complement can have an important role in vespid-induced anaphylaxis, exacerbating the reaction due to the activation of complement by proteases present in the venom and adding to the IgE-mediated reaction.

The molecular pathway of bradykinin reactions has been elucidated in animal models and involves an increase in heparin and Factor XII-driven contact system that results in the production of bradykinin and ultimately accounts for the increased vascular permeability (clinically, hypotension and desaturation). These symptoms have been associated with contamination of heparin with oversulfated chondroitin sulfate.

**Biomarkers for diagnosis of anaphylaxis**

**Skin tests (STs)**

A careful history is important for the identification of culprit allergens. The ST is a highly specific test for Type I reactions, which is used to identify sensitization for numerous allergens including airborne, food-related, drugs (including platins), β-lactams, general anesthetics, and Hymenoptera venom triggers.

Skin testing is considered safe for patients with a history of anaphylaxis and mastocytosis, provided comorbidities such as asthma are controlled. Medications such as β-blockers and angiotensin-converting enzyme (ACE) inhibitors may introduce greater risk for skin testing in case of a serious reaction; therefore, they should be discontinued before testing. Patients with CRRs and complement-activation reactions are likely to have negative ST results due to non-IgE mechanisms; however, the use of ST is still useful to identify
patients who may convert from CRR to Type I reactions or those with mixed reactions.\textsuperscript{38,52}

There should be a 4- to 6-week gap between anaphylactic reaction and ST due to the temporary loss of cutaneous activity following anaphylaxis; full restoration may take up to 6 weeks. However, due to treatment schedules, exceptions are made to expedite skin testing to 2 weeks post reaction, which should be sufficient to restore cutaneous reactivity; however, negative results may be inconclusive and demand further evaluations.\textsuperscript{53} For drug allergy, skin testing should be undertaken after resolution of clinical symptoms and clearance of culprit drug and rescue medication from the circulation.\textsuperscript{54} In case of Hymenoptera hypersensitivity, test reactivity may be falsely negative for approximately 6 weeks following such a reaction; therefore, STs should be performed later.\textsuperscript{55}

Both ST and antigen challenge tests are reliable in vivo tests. However, not all allergenic compounds are present in the current skin testing extracts; therefore, the gold standard to clear an allergy after negative skin testing is a challenge. Patients with a convincing history of anaphylaxis and evidence of sensitization to a specific food should not undergo oral food challenges due to the high risk of anaphylaxis. For those with an equivocal history, low or moderate evidence of sensitization, or both, might benefit from a physician-monitored incremental oral food challenge. A positive (failed) challenge provides a sound basis for continued avoidance of the food. A negative (passed) challenge allows introduction or reintroduction of the specific food into the patient’s diet.\textsuperscript{56}

For evaluation of penicillin allergy, skin testing of both major and minor determinants is required because patients are likely sensitized to minor determinants that are not currently commercially available in the US.\textsuperscript{57,58} For patients with a distant history of penicillin allergy and symptoms inconsistent with Type I reactions, a direct oral challenge with penicillin may be indicated.\textsuperscript{59-63} Reactions to beta-lactams can be by reactions to the beta-lactam ring or by reactions to its side-chain, so that there may be cross-reactivity dependent on each of these structures. It has been described patients capable of tolerating penicillin, who present anaphylactic reactions to other \(\beta\)-lactams that share the same side-chain, such as some aminopenicillins and cephalosporins.\textsuperscript{64,65} Efforts are currently underway to generate suitable ST reagents and establish the predictive value of cephalosporin STs.\textsuperscript{66}

The specificity and sensitivity of mAb skin testing have not been defined because the allergenic components/epitopes are not yet defined and non-IgE-mediated mechanisms are believed to play a role. For chimeric mAbs, such as rituximab and infliximab, mouse epitopes are thought to be involved in the allergic response, and ST results are positive in 60–70% of patients with Type I and mixed reactions for rituximab; however, only 50% of patients with infliximab-induced Type I reactions have positive ST results.\textsuperscript{67} The negative predictive value for most mAbs is not known. Of 23 patients desensitized to trastuzumab, infliximab, or rituximab, 13 had positive ST results, although all had symptoms compatible with Type I or mixed reactions.\textsuperscript{67} Another study showed that 58/106 patients treated with mAbs had STs, and 41% of those were positive. Per phenotype, ST was positive in 44% of Type I reactions, 11% of CRRs, and 54% of the mixed reactions. A positive ST was associated with greater severity of initial reaction. These results indicate the value of ST for mAbs as well as the need for continued research.\textsuperscript{38}

**Serology and specific IgE**

Many patients with allergic disorders (eg, atopic dermatitis, atopic asthma, allergic rhinitis) have elevated levels of total IgE.\textsuperscript{68} This elevation is not specific and low levels cannot be used to exclude the presence of atopic disease, because patients can still have local production of allergen-specific IgE in the tissues, and total IgE by itself is rarely adequate to diagnose allergic disease.\textsuperscript{69-71}

Measurement of allergen-specific IgE is guided by the results of skin and/or serum testing.\textsuperscript{69} Specific IgE levels can be measured for food, environmental allergens, Hymenoptera venom, and drugs, including antibiotics and chemotherapy.\textsuperscript{72,73} They are not especially useful to identify and monitor food allergies because of their crude nature, lack of potency assessment, and variability among manufacturers and lots.\textsuperscript{74} Furthermore, skin testing may not be indicated due to diffuse skin diseases, significant dermatographism, inability to wean off medications interfering with the testing, or use of an extract believed to have a high probability of inducing a systemic reaction in the subject to be tested.\textsuperscript{69,75}

A poor correlation between the IgE titer with ST result and the risk of anaphylaxis has been shown in previous studies; therefore, there is no evidence that either diagnostic test could accurately predict a severe allergic reaction in children or adults.\textsuperscript{76}

Hymenoptera venom–specific IgE has high sensitivity and specificity, and components of the venoms are under recent evaluation, with a few components commercially available for clinical use. It has become apparent that patients treated with venom extracts may have severe anaphylaxis when stung in the field, which may be attributed to sensitization to minor determinants, such as Api m 10, which is absent in most current vaccines.\textsuperscript{77,78} Patients with specific IgE to Hymenoptera venoms who have been sensitized to major and minor determinants might not be protected after vaccination,
and increasing the dose of venom has been recommended. The most effective test to determine the effectiveness of immunotherapy is the sting challenge test with live Hymenoptera; however, its safety is controversial.

Penicillin-specific IgE has low sensitivity and is currently reserved for patients with near-fatal anaphylaxis, in whom skin testing is deemed unsafe. Measurement of specific IgE to other β-lactams, such as cephalosporins, has been used to assess cross-reactivity, but its clinical value has not been defined. Specific platin IgE has been shown to have lower sensitivity than skin testing, but has a higher specificity. A major advantage of specific IgE for platins is the ability to detect IgE antibodies shortly after the reactions and without the need to wait several weeks to determine ST reactivity, which can delay treatment to chemotherapy. Another advantage of specific IgE is that it can detect cross-reactivity with other similar drugs, for example, patients sensitized to oxaliplatin had specific IgE for other platins (carboplatin and cisplatin) without previous exposure.

**Component-resolved diagnostics**

Advances in precision medicine have made it possible to identify and characterize some molecules present in the allergenic extracts, and this has resulted in component-resolved diagnosis which has changed our understanding of sensitization profiles and cross-reactivity as well as improved our ability to identify specific clinical phenotypes. In addition, it has allowed us to determine the relative risk of the severity of reactions in specific cases, such as soy, peanut, and hazelnut allergies, as well as predict the severity of allergic reaction – as in the case of Ara h 1, 2, and 3 associated with peanut-induced anaphylaxis, in contrast to patients with specific IgE to Ara h 8, 9, and 10 who might have oral allergy syndrome caused by cross-reactivity with tree pollen allergens and might not be at risk for anaphylaxis. Geographic variations have been seen – for instance, in the Mediterranean area, systemic reactions to hazelnut are generally mediated by Cor a 8, a lipid transfer protein (nsLTP), whereas reports from the US and Northern Europe have associated sensitization to Cor a 9 (an 11S globulin) and Cor a 14 (a 2S albumin) with severe hazelnut allergy in children. More studies are needed to validate the predictive values across different races, sex, and ethnic backgrounds.

Studies show that component-resolved diagnostics (CRD) offered greater specificity, but decreased sensitivity, in foods; therefore, its use is complementary and should not be used alone to rule out food allergy.

In relation to pollen allergies, the utility of CRD focuses on the correct identification of species-specific markers (Bet v 1 can identify individuals allergic to the Betulaceae family; Ole e 1, those allergic to the Oleaceae family; Cup a 1, those allergic to the Cupressaceae family; and Pla a 1, those allergic to the Platanaceae family), especially in patients with multiple sensitization patterns secondary to cross-reactivity due to the presence of panallergens (polcalcin, profiling, or nsLTP). In cases of multiple pollen sensitization, responses are better to allergen-specific immunotherapy when it is prescribed on the basis of species-specific molecular markers with clinical relevance for each patient.

In case of Hymenoptera allergy, CRD has become a very useful tool to distinguish between genuine sensitization and cross reactivity, because allergen sources contain potentially cross-reactive allergens between honey bee and wasp, such as Api m 2, Ves v 2 (hyaluronidases), Api m 5, Ves v 3 (dipeptidylpeptidases), Api m 12, Ves v 6 (vitelligenins), and marker allergens that are specific for honey bee venom (Api m 1, Api m 3, Api m 4, and Api m 10) or yellow jacket venom (Ves v 1 and Ves v 5); these markers allow discrimination in clinical situations in which patients have a multiple sensitization profile.

**Basophil activation test**

Basophils and mast cells originate from a common progenitor cell in bone marrow and share similar phenotypic/biochemical characteristics: they express high-affinity IgE receptors and contain special cytoplasmic granules. Basophils can be easily assessed because they are circulating granulocytes that have responded to allergic stimuli by migrating and accumulating at sites of allergic inflammation. Mast cells, unlike basophils, leave the bone marrow immature and complete their maturation in peripheral tissues, where they ultimately reside. Therefore, evaluation of human mast cells is limited to biopsy specimens from specific tissues.

The basophil activation test (BAT) is a blood test used to diagnose IgE-mediated reactions to allergens such as food, environmental allergens, Hymenoptera venom, or drugs. BAT is a flow-cytometry–based functional assay that detects upregulation of the basophil activation surface markers CD63 and CD203c following exposure to an antigenic stimulus. Because both mast cells and basophils are sensitized with the same repertoire of IgE, BAT is considered a true reflection of sensitized mast cells.

Currently, BAT is commercially available but has not been standardized or approved by the US Food and Drug Administration.

BAT has had success in evaluating immediate reactions to β-lactams, muscle relaxants, other drugs, as well as the diagnosis and monitoring of Hymenoptera venom allergies. BAT is not recommended for patients with a
history of multiple reactions, NSAID hypersensitivity, or those with food allergies because of their increased histamine release at baseline.108

In a study with 15 patients allergic to platinum-containing compounds who were undergoing drug desensitization, BAT provided reliable information with regard to sensitization and upregulation of CD203c expression. Furthermore, reaction severity has been correlated with a higher expression of CD63, demonstrating that this technique can be used as a biomarker for desensitization.109

Tryptase
Tryptase is a serine protease and the most abundant secretory mediator formed and stored in human mast cells and basophils. The in vivo biologic activities of mature tryptase remain uncertain, but in vitro activities include generation of complement anaphylatoxins, inactivation of fibrinogen, and stimulation of a variety of different cell types. In addition to its release, it amplifies the allergic response.

The rise of tryptase levels can be detected in serum 30 minutes after the initial symptoms of anaphylaxis and peaks 1–2 hours post initiation of the reaction. Tryptase elevation is transient and typically resolves within 24–48 hours. Commercial immunoassays allow for detection of total (baseline release, reflecting mast cell and basophil burden) and mature tryptase (released only at the time of activation); however, they do not discriminate between the two. Increases above the normal range of 11.4 ng/mL are indicative of either acute mast cell/basophil activation or increase in total mast cell number;110 therefore, a baseline tryptase level is required 2 weeks post anaphylaxis. Tryptase levels ≥2 ng/mL + 1.2× baseline are considered significantly increased for patients with a low baseline tryptase.111,112

Total tryptase levels can be elevated (>20 ng/mL) in most patients with systemic mastocytosis (SM) – a clonal disorder associated with mutation of the membrane tyrosine kinase KIT; however, it is seen in other conditions such as hematologic disorders (acute myelocytic leukemia, myelodysplastic syndromes), immunologic disorders (hypereosinophilic syndrome), severe renal failure, or inherited variations such as familial tryptasemia – a recently characterized disease.113,114

Tryptase specificity is high whereas its sensitivity is low due to its release from different mast cell and basophil subsets, depending on the trigger. Tryptase levels are lower in mucosal mast cells than in cutaneous and perivascular mast cells, and anaphylactic reactions to intravenous drugs can elicit greater and more persistent increases than oral triggers, such as foods.

If anaphylaxis is suspected, blood sampling for tryptase measurement should be done between the first 30 minutes and 3 hours of reaction initiation to capture the maximum tryptase value.115 Elevations correlate with hypotension and support the diagnosis of anaphylaxis, although normal levels do not exclude the diagnosis.116,117

Other inflammatory mediators
Other mast cell/basophil mediators can be released during anaphylaxis including histamine, which is the only preformed granule mediator of these cells with vasoactive activity and direct spasmogenic action on the smooth muscle.

Elevation in plasma/urine histamine is consistent with anaphylaxis, although it is not exclusive, because other conditions can also have elevated levels without mast cell/basophil activation.115 Both histamine and its metabolite methylhistamine can be measured in 24-hour urine collection; however, the sensitivity is low because of the difficulties in timing 24-hour urine collections to symptom onset.

The contribution of PAF to anaphylaxis, which has been studied in mice, suggests a synergistic effect between histamine and PAF.19 A recent human study indicated an inverse correlation between serum PAF and acetylhydrolase levels (the enzyme that metabolizes and inactivates PAF) with the severity of anaphylaxis: low enzymatic levels were associated with high PAF levels, severe hypotension, and fatal and near-fatal anaphylaxis.118

Levels of other serum inflammatory mediators such as TNF-α, IL-6, and IL-1b can be elevated in patients with CRRs and anaphylaxis, but their sensitivity or specificity have not yet been validated.38 These inflammatory mediators provide insight into the phenoendotype of reactions and can help guide recommendations for desensitization protocols and premedications.50

Prostaglandin D2 and leukotrienes E4 and C4 can be measured in 24-hour urine collection. Despite high specificity, the sensitivity might be low due to the difficulties in timing 24-hour urine collections to symptom onset. However, prostaglandin D2 levels cannot be useful in patients receiving cyclooxygenase inhibitors.

Other mast cell proteases, such as chymase and carboxypeptidase, have been detected during anaphylaxis, although no commercial assays are available to date.
Patients at risk
Food-induced anaphylaxis and food-triggered exercise-induced anaphylaxis

Predictors for anaphylaxis risk have not been elucidated; one of the most important known risk factors associated with fatal anaphylaxis is asthma.119–121 Food-induced anaphylaxis affects both sexes equally, and fatal food-induced anaphylaxis occurs most often in adolescents and young adults who are unaware of their allergy, with the largest culprit being tree nuts.122

Anaphylaxis can be induced by many foods, the most common including cow’s milk, hen’s eggs, peanuts, tree nuts, fish, shellfish, soy and wheat, with variations depending on geography and local dietary patterns. Food-induced anaphylaxis is most common in children, but can occur in people of any age.123

In a study of 1,094 patients with peanut and tree nut allergy conducted in the UK, severe atopic disease was associated with the most severe reactions. Severe pharyngeal edema was associated with severe rhinitis; life-threatening bronchospasm was associated with severe asthma; and altered mental status was associated with severe eczema. These associations were independent of sex and age, although adults were 9 times more likely to have severe reactions than children and, of 122 patients in whom ACE and aminopeptidase levels were measured, patients with low levels had a greater number of severe reactions, highlighting the role of bradykinins in food-induced anaphylaxis as well as the need to discontinue ACE inhibitors in patients with food allergies.124

In a systematic review and meta-analysis that involved data from North America, Europe, and Australia, the estimated incidence of fatal food anaphylaxis in a food-allergic individual was 1.81 (95% CI 0.94–3.45) per million person-years, confirming that the incidence of fatal food-related anaphylaxis had little impact on the overall mortality risk in this group.125

In an Australian study, 4,453 infants with eczema were evaluated to characterize their risk of challenge-proven food allergy. They found that eczema was a strong risk factor for IgE-mediated food allergy, and the severity of eczema was associated with greater risk of food-induced allergies. They hypothesized that increased cutaneous exposure to food allergens in infants with weakened skin-barrier function may increase the risk of food sensitization.126

Recently, a multicenter study in the US evaluated allergic reactions in oral challenges for individuals with food allergies. Of the 6,377 oral provocations undertaken, the rate of allergic reactions was 14% (95% CI 13–16%) and the pooled estimate of anaphylaxis was 2% (95% CI 1–3%). Peanut was the most frequently involved allergenic food in the Northeast, Midwest, and West, whereas egg was the most frequent in the South. This showed that the likelihood of anaphylactic reaction in allergic individuals is low and geographical variations between trigger foods are present.127

Food-dependent exercise-induced anaphylaxis (FDEIA) is a disorder in which symptoms develop only if exertion takes place within a few hours of eating certain food(s) to which the patient is sensitized.128,129 This has been reported in patients of all ages, although most cases are described in adolescents and young adults, with wheat and omega-5 gliadin identified as the dominant triggers. The mechanisms are not fully understood; however, elimination of wheat before exercise reduces reactions.130–132

More recently, food ingestion associated with other cofactors, such as alcohol or the menstrual period, was found to induce anaphylaxis, expanding the understanding of FDEIA as a syndrome in which exercise might not be necessary.133

Mast cell activation disorders

Mast cell disorders are conditions in which mast cells are either increased in number (clonal mast cell disorders), hyper-reactive (non-clonal mast cell disorders), or both (Figure 2).134

Mast cells activate and accumulate in tissues due to a gain-of-function mutation, commonly in the KIT receptor gene that codes a tyrosine kinase transmembrane receptor involved in the regulation of crucial mast cell functions such as differentiation, activation, and survival. Upon receiving a trigger, they release mediators inappropriately, interfering with normal function, causing a variety of localized and systemic symptoms.134,135

Mast cell activation syndrome (MCAS) applies to all disorders (including anaphylaxis) that appear as a consequence of the release of vasoactive mediators by activated mast cells. Based on previous consensus, MCAS can be classified into three categories:112,136

1. Primary MCAS, including SM and monoclonal MCAS (MMAS).
2. Secondary MCAS.
3. Idiopathic MCAS.

All of the criteria should be present to make a diagnosis of MCAS (Table 1).

In primary MCAS (increased mast cells number), the presence of mast cell clones in the bone marrow of the affected individual must be demonstrated. In most patients (>95%) with SM and MMAS, mast cell clonality can be established by detecting KIT receptor-activating mutations. On the other hand, mast cells in secondary and idiopathic MCAS (increased...
Phenotypes, endotypes, and biomarkers of anaphylaxis

Figure 2 Mast cell activation syndrome.

Notes: Adapted from original provided by Dr Raied Talal Hufdi, Division of Rheumatology, Immunology and Allergy; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Abbreviations: AHN, associated hematologic neoplasm; BM, bone marrow; EDS, Ehlers-Danlos Syndrome; GI, gastro-intestinal; IgE, immunoglobulin E; IgG, immunoglobulin G; IL, interleukin; MC, mast cell; MCAS, mast cell activation syndrome; MCL, mast cell leukemia; MMAS, monoclonal mast cell activation syndrome; NSAIDs, nonsteroidal anti-inflammatory drugs; PAF, platelet-activating factor; POTS, Postural Orthostatic Tachycardia Syndrome; RCM, radio contrast medium; SM, systemic mastocytosis; TMPE, telangiectasia macularis eruptiva perstans; TNF-α, tumor necrosis factor alpha; WHO, World Health Organization.
activation) are normal, and symptoms of mast cell activation are related to other, secondary underlying conditions that activate these cells (allergies, neoplasms, inflammatory or autoimmune diseases, or unknown factors).137

Overall, 30% of patients with mastocytosis can present with anaphylaxis with known (including hymenoptera venom–induced anaphylaxis) or unknown triggers.138–140 Due to the lack of cutaneous manifestations (flushing, maculopapular rash in the form of urticaria pigmentosa, etc.), the diagnosis is often missed or delayed.141 Patients with syncope, hypotension, or cardiovascular collapse with severe anaphylaxis after Hymenoptera sting even with normal baseline tryptase levels should be evaluated for the KIT D816V mutation, which is present in >95% of patients with SM. In patients with positive KIT D816V mutation, a bone marrow biopsy is recommended.142–145 A tryptase level >20 ng/mL at baseline 4–6 weeks after an anaphylactic event is a minor criterion of SM and an indication for bone marrow biopsy.143 Other criteria for the diagnosis of SM are shown in Table 2. Systemic symptoms of mast cell mediator release such as osteoporosis, bone fractures, and gastrointestinal symptoms, including bloating and diarrhea, can be present for many years and are typically unrecognized.14

Mastocytosis and MCAS can be identified as a cause of idiopathic anaphylaxis due to the fact that they can be controlled with tyrosine-kinase inhibitors.26

Treatment with venom immunotherapy (VIT) – if an IgE mechanism can be demonstrated, with or without omalizumab – provides a dramatic increase in patient safety when re-stung.143,146,147 Although there is no increase in the prevalence of drug allergy in patients with clonal mast cell disorders,148 reactions to NSAIDs are greater in these patients and can present as anaphylaxis.149

**Drug allergy**
The increase in anaphylaxis to drugs in the last 20 years is thought to be due to the increase in the variety and use of drugs. Some of these drugs have relatively high rates of HSRs including antibiotics, chemotherapeutic agents, mAbs, replacement factors, and biological agents. The pattern of presentation for HSRs continues to evolve, and new classifications have been created to encompass them.14,36,38

Medications are typically cited as among the most common triggers of fatal HSRs without age restriction and have been documented frequently in both pediatric and elderly populations.150 According to the European Anaphylaxis Registry, drugs were the third most frequent elicitor of anaphylaxis after food and insect venoms in the pediatric age group.151 Recently, a study from Turkey reported that 84 (15%) of 561 children were diagnosed with drug allergy; the most common drugs included β-lactam antibiotics (33%; penicillin, amoxicillin–clavulanic acid, ceftriaxone, cefixime, cefaclor, and piperacillin–tazobactam), NSAIDs (25%), chemotherapeutics (19%; asparaginase, oxaliplatin, etoposide, and docetaxel), biologic agents and enzymes (12%; rituximab, eculizumab, and enzymes like galsulfase and idursulfase), anesthetic and neuromuscular blocking agents (5%; propofol, midazolam, and rocuronium), and others (6%; ranitidine, triptorelin, cyclopentolate, iopromide, and Factor 9).14

On the other hand, it has been reported that older patients have both – higher rates of drug-induced anaphylaxis and an increased risk of severe reactions.152–154

Antibiotics are still the most common drug to cause anaphylaxis. IgE-mediated mechanisms are most commonly

---

**Table 1 Proposed criteria for mast cell activation syndrome (all 3 must be present)**

1) Episodic multisystem symptoms consistent with mast cell activation
2) Appropriate response to medications targeting mast cell activation
3) Documented increase in validated markers of mast cell activation systemically (ie, either in serum or urine) during a symptomatic period, compared with the patient’s baseline values*

**Notes:** *Documentation of a single meaningful increase in tryptase level is sufficient, whereas it is recommended to document at least two measurements of increased levels of other markers. Reproduced from Journal of Allergy and Clinical Immunology, Volume 140 (Edition 2), Akin C. Mast cell activation syndromes, pages 349–355, Copyright 2017, with permission from Elsevier.14*

**Table 2 WHO criteria for SM**

<table>
<thead>
<tr>
<th>SM criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major SM criteria</strong></td>
</tr>
<tr>
<td>Multifocal dense infiltrates of MCs (&gt;15 MCs in aggregates) in BM biopsies and/or in sections of other extra-cutaneous organ(s) including gastrointestinal tissues</td>
</tr>
<tr>
<td><strong>Minor SM criteria</strong></td>
</tr>
<tr>
<td>1) In total, 25% of all MCs are atypical cells (types I or II) on BM smears, or are spindle-shaped in MC infiltrates detected on sections of visceral organs</td>
</tr>
<tr>
<td>2) KIT point mutation at codon 816 in the BM or another extra-cutaneous organ</td>
</tr>
<tr>
<td>3) MCs in BM or another extra-cutaneous organ expressed CD25 and/or CD2</td>
</tr>
<tr>
<td>4) Baseline serum tryptase level &gt;20 ng/mL (in case of an unrelated myeloid neoplasm, item 4 is not valid as an SM criterion)</td>
</tr>
</tbody>
</table>

If at least one major and one minor or three minor SM criteria are fulfilled, a diagnosis of SM can be established

SM criteria were defined by the WHO in 2001 and have been confirmed in the WHO updates of 2008 and 2016

**Note:** Adapted with permission of American Society of Hematology, from Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts, Valent P, Akin C, Metcalfe DD, Colume 129 (Edition 11), 2017; permission conveyed through Copyright Clearance Center, Inc.159

**Abbreviations:** MCs, mast cells; BM, bone marrow; SM, systemic mastocytosis; WHO, World Health Organization.
implicated in β-lactam allergy,63 and certain populations, such as patients with cystic fibrosis and patients treated with multiple courses of antibiotics, are at high risk.155

Patients presenting with anaphylaxis during anesthesia or after quinolone use for whom an IgE mechanism cannot be demonstrated by skin testing may have either increased protein levels or functional MRGPRX2 receptors that can bind and activate mast cells without IgE mediation; however, the participation of MRGPRX2 receptors has not been confirmed in human subjects.27–29

Due to the increased use of chemotherapies and targeted therapies, including mAbs, drug HSRs and anaphylaxis have increased dramatically worldwide, preventing the use of first-line therapies and affecting patient survival and quality of life.156 Some of the most immunogenic chemotherapies are carboplatin, cisplatin, oxaliplatin, and taxanes for ovarian, lung, breast, colon, and prostate cancers.157

Platins can elicit Type I reactions and typically require repeated exposures.55,88,158 Oxaliplatin is an exception to this, and first lifetime exposure reactions have been documented as well as CRRs and mixed reactions.159 Taxanes can induce similar reactions with atypical symptoms, such as back pain, through IgE- and non–IgE-mediated mechanisms. Cremophor and Polysorbate 80, used as diluents, are thought to be implicated in non–IgE-mediated reactions, which can occur at first or second lifetime exposures.156,158,160 In a recent study, STs conducted on 145/164 patients treated with taxane hypersensitivity were used to establish HSR risk and treatment protocol.161

Furthermore, mAbs are used in the treatment of neoplastic, autoimmune, and inflammatory diseases, and their clinical applications are becoming broader. Targets for these drugs include CD20, HER-2, epidermal growth factor receptor, IL-6 receptor, TNF-α, CD30, vascular endothelial growth factor A, programmed cell death protein 1/programmed death ligand L, IL-4, IL-5, IL-13, and IgE, among others.162 Although chimeric mAbs, such as rituximab and infliximab, present with the highest incidence of reaction, humanized and human mAbs – although less immunogenic – are engineered with mouse glycosylation patterns, which can result in allergenic determinants. Even with fully human mAbs, such as adalimumab and ofatumumab, anaphylaxis has been reported.18,162 Clinical presentation included a spectrum of atypical symptoms such as CRRs, infusion-related reactions, and mixed reactions that present with chills, fever, and generalized malaise followed by hypotension, desaturation, and cardiovascular collapse.106,164 These reactions can occur at first exposure but have also been seen after several exposures.67,163–165 Mixed reactions occur when these symptoms are associated with Type I symptoms and mast cells/basophils involvement or positive ST results, demonstrating an IgE mechanism in addition to the release of IL-6.89

Anaphylaxis at first exposure has been observed with cetuximab in patients with preformed carbohydrate galactose-a-1,3-galactose IgE antibodies due to tick exposure (Amblyomma americanum).166 Galactose-a-1,3-galactose is expressed on non-primate mammalian proteins and is present on the cetuximab heavy chain.167

Patients under treatment with β-blockers and ACE inhibitors
Evidence for β-blockers and ACE inhibitor treatment with anaphylaxis is sporadic and limited to retrospective data. There are no prospective trials to explain the relationship between these drugs and anaphylaxis.168 Theoretically, both β-blockers and ACE inhibitors may affect the patient’s likelihood of developing anaphylaxis and their ability to respond to treatment.169–171

The relationship between antihypertensive medication and the severity of anaphylaxis was associated with the conclusion that β-blocker, ACE-inhibitor, diuretic, and antihypertensive medication used in combination was significantly associated with grade 3 anaphylaxis (three or more organ/system involvement; OR, 2.8; 95% CI, 1.5–5.2; P = 0.0008), showing that the use of these drugs increased the severity of anaphylaxis.172

A telephonic survey conducted on German patients with a history of severe anaphylaxis had identified monotherapy with β-blockers or ACE inhibitors as a risk factor for severe anaphylaxis, which was more pronounced with combination therapy. In mouse models, the role of potential cofactors on anaphylactic responses confirmed that β-blocker and ACE inhibitors have modest anaphylaxis-promoting activities as single substances, but clearly display potentiating effects when administered in combination.173

The current recommendation is to avoid β-blockers and ACE inhibitors in patients at risk for anaphylaxis with no cardiovascular disease. Patients with cardiovascular disease should continue with β-blockers and ACE inhibitors, due to the proven decrease in mortality and increased life expectancy of this therapy.168

Latex allergy
Latex in gloves, condoms, and surgical materials has been shown to induce anaphylaxis,174 and cross-reactivity has been demonstrated with fruit allergens.175 In a recent publication,
which looked at patients undergoing surgical procedures, latex was reported as the second most common cause of anaphylaxis (20%) after neuromuscular blocking agents (47%),\(^{176}\) and the risk increases with exposure.\(^{177}\)

Although STs for latex have higher specificity (96–100%) and sensitivity (95–99%) than in vitro tests, they have been associated with anaphylactic events and are, therefore, discontinued in the US;\(^{178}\) diagnosis relies on serum IgE.

With the advent of latex-free facilities and the use of non-latex gloves, the incidence of latex-induced anaphylaxis has decreased.\(^{179}\)

**Hymenoptera venom**

Epidemiological studies have estimated the prevalence of systemic reaction to Hymenoptera stings from 0.3 to 8.9%, and insect stings as 1.5–34.1% of all-cause anaphylaxis. Cases of fatal insect-sting anaphylaxis account for approximately 20% of fatal anaphylaxis from any cause.\(^{82}\)

Risk factors for severe HSRs were determined from a European study of 962 patients with systemic reactions to Hymenoptera sting: elevated baseline tryptase levels (suggestive of MCAS), ACE inhibitor therapy, male, vespid sting, history of milder reactions, and systemic reactions to honey bee stings.\(^{180}\) Other factors determining the severity of reaction to Hymenoptera sting include advanced age as well as preexisting cardiovascular and respiratory disease.\(^{142}\) Mastocytosis may provoke fatal anaphylaxis despite VIT; however, so far, this has been observed only after discontinuation of treatment.\(^{82}\)

Hymenoptera anaphylaxis may be the presenting symptom of mastocytosis in an otherwise healthy individual.\(^{142}\) The mechanism of increased susceptibility to Hymenoptera venom anaphylaxis in mastocytosis has not been elucidated, but explanations include the following: 1) increased number of mast cells amplifying the severity of the reaction resulting from high mast cell mediator release; 2) perivascular location of the mast cells, providing direct access to the intravascular compartment; 3) D816V-mutant KIT amplifying the IgE-mediated reaction; and 4) additive direct (non-IgE-mediated) mast cell-activating properties of the Hymenoptera venom, including phospholipase A2 (Figure 3).\(^{142}\)

Furthermore, VIT with premedication has been suggested to increase VIT safety. Similarly, omalizumab has been shown to decrease the severity of allergic anaphylaxis following VIT administration in patients who had not previously tolerated immunotherapy,\(^{181}\) including patients with mastocytosis.\(^{146,147,182}\)

---

**Figure 3** Mast cell defects may collectively lead to increased risk for anaphylaxis in response to hymenoptera venom in patients with clonal mast cell disease.

*Note:* Reproduced from The Journal of Allergy and Clinical Immunology: In Practice, Volume 3 (Edition 3), Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? Pages 350–355, Copyright 2015, with permission from Elsevier.\(^{142}\)

**Abbreviations:** IgE, immunoglobulin E; LTC4, leukotriene C4; PGD2, prostaglandin D2.
Phenotypes, endotypes, and biomarkers of anaphylaxis

Progestogen hypersensitivity

Progestogen hypersensitivity is a new terminology proposed for the already known autoimmune progesterone dermatitis – a rare and under-recognized disease that affects women of childbearing age. Symptoms can appear at any age, but most frequently appear in the third decade of life. A broader presentation of cyclical symptoms, including asthma and anaphylaxis, has been described during the progesterone surge. According to the cases previously reported, the onset of symptoms in 75% of patients occurs during the progesterone peak of the menstrual cycle (Figure 4). The lack of specific IgE against progesterone does not necessarily rule out the diagnosis. Endogenous and exogenous sources of progesterone can be allergenic triggers, and desensitization to progesterone has reversed infertility.

One publication reports that four of six women with dermatitis or anaphylaxis related to the luteal phase of the menstrual cycle (some of them related to in vitro fertilization) and positive STs to progesterone were successfully desensitized to this hormone; this is the first evidence of hormonal desensitization that has culminated in successful pregnancies or good tolerance to oral contraceptives.

Cardiovascular diseases

Kounis syndrome is diagnosed when an acute coronary syndrome co-incidently occurred with a HSR following an allergenic event. It is thought to be caused by inflammatory mediators released by mast cells. The syndrome depends on the subtype of the coronary artery disease present, and symptoms reverse without sequelae within a few hours of the initial anaphylactic symptoms. Coronary damage can occur in severe episodes, but is rare. Use of intravenous epinephrine can have a detrimental role in patients with allergic angina, because of worsening myocardial ischemia, prolongation of the QTc interval, induction of coronary vasospasm, and arrhythmias; however, if necessary, intramuscular doses of epinephrine can be given.

Takotsubo is defined as stress cardiomyopathy during anaphylaxis secondary to a rapid elevation of circulating catecholamines released in middle-aged women and is characterized by transient regional systolic and diastolic dysfunction of the left ventricle leading to a variety of wall motion abnormalities. This can lead to fatal cardiac arrhythmias with heart failure. Treatment is focused on stabilizing the acute onset and correct management of complications.

Treatment and prevention

Epinephrine is the cornerstone in the acute treatment of anaphylaxis, and delayed administration is associated with increased mortality. The recommended dose of epinephrine is 0.01 mg/kg of a 1 mg/mL (1:1,000) dilution, to a maximum dose of 0.5 mg in an adult or 0.3 mg in a child, and can be repeated three times every 5–15 minutes. Patients should lie down with their legs elevated to avoid the empty inferior vena cava/empty ventricular syndrome and sudden death.

Epinephrine leads to vasoconstriction, increased peripheral vascular resistance, and decreased mucosal edema through the α1-adrenergic receptor, which is present in many tissues (including mast cells). It is the only drug with these effects among the medications used for the treatment of anaphylaxis, and clinically, it manifests as relief of airflow obstruction in the larynx as well as the lower airways, prevention of hypotension, and shock.

In 2014, a review analyzed how the inadequate use of auto-injectable epinephrine could affect the management of anaphylaxis. Several critical points established by the authors included: problems in properly recognizing and diagnosing the disease; when it was recognized, it was treated with epinephrine, but even in these cases, the use of epinephrine was suboptimal; the patients did not carry auto-injectable epinephrine, or they were not trained for its use and there was no access to this drug in public spaces such as airports, schools, sport stadiums, and restaurants. Based on these

Figure 4 Onset of symptoms in patients during the menstrual cycle in progesterone hypersensitivity.

Note: Adapted from Fertility and Sterility, Volume 95 (Edition 3), Prieto-Garcia A, Sloane DE, Gargiulo AR, Feldweg AM, Castells M. Autoimmune progesterone dermatitis: clinical presentation and management with progesterone desensitization for successful in vitro fertilization, Pages 1121.e9–e13, Copyright 2011, with permission from Elsevier.
findings, suggestions for approval included training health professionals and promoting the availability of epinephrine in public places to prevent cases of fatal anaphylaxis.196

If a patient presents with acute urticaria, antihistamines are recommended without the use of epinephrine unless another organ system is involved. In the case of urticaria with involvement of another organ system, the diagnosis of anaphylaxis should prevail, and epinephrine is the drug of choice.

Long-term treatment after an acute episode of anaphylaxis includes educating and training the patient and their family about the disease and the use of auto-injectable epinephrine32 (Table 3). Critically ill patients who have experienced an episode of anaphylaxis should be evaluated by an allergist, and triggers should be identified using allergen STs and/or measurement of allergen-specific IgE levels in serum.200 It is important to determine tryptase, both at baseline and during the reaction, to aid in a differential diagnosis.

Avoidance education based on the known trigger of anaphylaxis should be part of patient education. Anaphylaxis to stinging insects can be prevented by immunotherapy with the relevant insect venom(s), and anaphylaxis to certain medications can be overcome by desensitization.

For food allergy, the first step is to avoid the trigger and treat symptoms in case they appear. Oral immunotherapy for food-induced anaphylaxis is under investigation. In the US, results of a peanut protein oral immunotherapy (OIT) Phase III clinical trial in children aged 9–36 months demonstrated a good safety profile, with a decrease in specific IgE and increased tolerance, while achieving safe dietary reintroduction.201 A similar study reported sustained unresponsiveness following egg OIT, increasing the likelihood of tolerated unbaked eggs in diet,202 and a report from Europe using sublingual immunotherapy (SLIT) with Pru p3

Table 3 Preventive treatment of anaphylaxis

<table>
<thead>
<tr>
<th>Long-term treatment and prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Education</td>
</tr>
<tr>
<td>• Immunotherapy: environmental, food, Hymenoptera</td>
</tr>
<tr>
<td>• Anti-IgE</td>
</tr>
<tr>
<td>• Tyrosine kinase inhibitor (clonal mast cell diseases)</td>
</tr>
<tr>
<td>• Desensitization (drugs, chemotherapy, mAbs, iron, progesterone)</td>
</tr>
</tbody>
</table>

Abbreviation: IgE, immunoglobulin E.

Figure 5 Acute treatment of anaphylaxis.

Abbreviations: ACE, angiotensin-converting enzyme; CV, cardiovascular; Gl, gastrointestinal; IV, intravenous.
(the primary sensitizer in fruits and responsible for severe HSRs in the Mediterranean area) also demonstrated good tolerance after treatment not only to peach, but also showed immunological changes in allergic patients to Ara h9 – an LTP from peanut.203

Immunotherapy should be considered in all patients who have had a history of anaphylaxis after an insect sting, and who have a positive ST or a positive result to an in vitro test for venom-specific IgE antibodies.204 Immunotherapy in patients with mastocytosis has been shown to significantly reduce the risk of anaphylaxis after a re-sting.30,205 VIT is recommended indefinitely in patients with mastocytosis and Hymenoptera allergy because mastocytosis is a chronic disorder with no curative options and systemic reactions and sting-related fatalities have been reported in patients who discontinued immunotherapy.142

Omalizumab – an anti-IgE mAb – has been shown to be a successful treatment for idiopathic anaphylaxis with IgE-mediated disease, effectively reducing the number of episodes and improving quality of life.206

Several cases have demonstrated the benefits of omalizumab as a pretreatment in patients who have not previously tolerated immunotherapy – both in healthy individuals and MCAS patients.146,181,207

Drug desensitization is a groundbreaking procedure for the management of immediate drug HSRs. It protects patients against anaphylaxis – maintaining patients on first-line therapy and thus representing an important advance in the treatment and prognosis of their medical condition.14

Desensitization to drugs has been used, for the last 15 years, in thousands of cases, with safety and great efficacy in patients with anaphylaxis to chemotherapeutic agents, mAbs, and antibiotics without any deaths. Powerful inhibitory mechanisms are initiated at low antigen doses, which can dominate the activator pathways and prevent anaphylaxis.118,208–210 Drug desensitization should be considered the standard of care when allergic patients require first-line therapy.

In a 2018 study, 526 desensitizations were carried out with 16 different mAbs in 104 patients, showing that reactions during the procedure are rare (23%) and the majority are mild (Grade I), with a decrease in HSR severity. STs may be useful as a predictor of severity when results are positive. The study demonstrated that desensitization provides a safe and effective re-treatment option to continue first-line therapy.38

The largest desensitization study worldwide has reported that 370 highly allergic patients received 2,177 successful desensitizations to 15 drugs. Most importantly, carboplatin-desensitized patients had a non-statistically significant lifespan advantage over non-allergic control subjects, indicating that the efficacy of carboplatin was not reduced in allergic patients and that rapid drug-desensitization protocols are as effective as standard infusions.211 Based on the results of the 2,177 desensitizations, 93% had no or mild reactions, whereas 7% had moderate-to-severe reactions that did not preclude the completion of the treatment; there were no deaths.211 Desensitization to mAbs and antibiotics has been successfully undertaken in targeted populations, such as patients with cystic fibrosis, with similar protocols. On the other hand, desensitization to aspirin for aspirin-exacerbated respiratory disease has induced an increased sense of smell, prevented the regrowth of polyps, and helped stabilize asthma symptoms.212–214

Current issues with available treatment modalities

Glucocorticoids and antihistamines should be used as complementary treatment in anaphylaxis. They are not lifesaving (like epinephrine) and do not prevent or relieve upper airway obstruction, hypotension, or shock.32 Glucocorticoid and antihistamine administration should never delay the administration of epinephrine. The use of glucocorticoids and antihistamines alone as prophylactic agents cannot be recommended, as they do not prevent life-threatening reactions and their use has only been studied with radiocontrast HSRs.215

As mentioned previously, omalizumab has been demonstrated to be effective in patients who have episodes of food-induced, VIT-induced, and/or idiopathic anaphylaxis. In a selected group of patients, pretreatment with omalizumab is cost effective and allows the patient to be treated with fewer reactions.

Social aspects of treatment of anaphylaxis and quality of life

Quality of life of patients experiencing one or more episodes of food, medication, Hymenoptera venom, or exercise-induced anaphylaxis is a critical aspect of the patient’s treatment and management. It affects not only the patient but also their family, school, and workplace, as well as their traveling and other social interactions.216 Up to 12% of people who experience an anaphylactic shock can develop post-traumatic stress disorder, as well as long-term effects such as fear and anxiety that can dominate and restrict social, family, and professional interactions in adults and children.217–219 In particular, adolescents can present with high-risk behavior.220 Education of patients, health-care providers, and ED personnel can have a positive effect in all of these areas.221
**Conclusion**

Anaphylaxis should be considered when symptoms in two or more organs and/or sudden changes in vital signs occur in patients with or without evident exposure to allergens such as food, drugs including antibiotics, chemotherapy and mAbs, Hymenoptera stings, or environmental factors (ie, latex, animal dander, and pollen). Clinical manifestations do not always include skin and mucosal changes, and hypotension and shock may not be present. Non-typical symptoms such as pain, chills, rigors, and fever have been recognized as part of a new phenotypic expression of anaphylaxis during reaction to drugs such as chemotherapy and mAbs.

A new classification system based on precision medicine using phenotypes, endotypes, and biomarkers has expanded the Gell and Coombs classification to better identify and treat anaphylaxis.

Skin testing is a safe tool to identify sensitization to numerous allergens, even in high-risk patients, such as those with cancer, cystic fibrosis, and mastocytosis. Other biomarkers such as specific IgE, component-resolved diagnostics, and BAT are evolving as useful tools for the future.

The tryptase level – which can be detected from 30 minutes to 3 hours after the onset of a reaction – is the best biomarker at the present time which can also identify patients with clonal mast cell disorders.

Epinephrine is the cornerstone in the acute treatment of anaphylaxis, and delayed administration is associated with increased mortality.

Patients with drug-induced anaphylaxis should be considered candidates for desensitization if in need of first-line therapies. Desensitization can increase life expectancy and quality of life of patients with drug-induced anaphylaxis.

Allergists should educate patients and provide them with action plans and tools, including auto-injectable epinephrine. Education of all specialists and health-care providers in the symptoms, presentation, and acute management of anaphylaxis is key to increasing awareness of anaphylaxis.

Precision medicine requires further research on new biomarkers and exploration of new treatment modalities such as anti-IgE.

**Acknowledgment**

The authors did not receive compensation nor was the content of the article influenced in any way. Adamis Pharmaceuticals paid publication fees for the articles in this special issue on anaphylaxis.

**Disclosure**

Dr Teodorikez Wilfox Jimenez-Rodriguez has received grants from the Spanish Society of Allergy and Clinical Immunology, the Valencian Association of Allergy and Clinical Immunology, and the Medical Association of Alicante, Spain.

Marlene Garcia-Neuer reports no conflicts of interest in this work.

Leila A Alenazy has been sponsored by the College of Medicine Research Center, Deanship of Scientific Research, King Saud University.

Dr Mariana Castells has received consultancy fees from Sanofi, Genentech, Lytx Biopharma, Bentham Science, and UpToDate. The authors report no other conflicts of interest in this work.

**References**


94.NSMutableDictionary*


